Bristol-Myers Squibb (BMY) Tops Q4 EPS by 14c, Beats on Revenue; Offers FY26 Guidance

Go back to Bristol-Myers Squibb (BMY) Tops Q4 EPS by 14c, Beats on Revenue; Offers FY26 Guidance

Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2025

February 5, 2026 6:59 AM EST

PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE:... More